Could your own cells replace insulin shots? early trial aims to find out

NCT ID NCT07118475

ENROLLING_BY_INVITATION Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether insulin-making cells grown from a patient's own pancreatic tissue can be safely transplanted under the belly skin to reduce or replace insulin shots. Twenty-four adults with insulin-dependent type 2 diabetes will take part. The main goal is safety, but researchers will also check blood sugar control and insulin needs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous islet cells grown from the patient's own pancreatic tissue
What this could lead to: If successful, this could reduce or eliminate the need for daily insulin injections in some people with type 2 diabetes, offering a functional cure.
What could go wrong: This is a very early, small study (24 people) focused on safety. The cells may not work as hoped, and there are risks from the tissue collection procedure and transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES (INSULIN-REQUIRING, TYPE 1 OR TYPE 2) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES (INSULIN-REQUIRING, TYPE 1 OR TYPE 2) DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Zhongshan Hospital

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.